Relapsing-Remitting Multiple Sclerosis

Treatment with immediate release tablets of a non-covalent Bruton’s tyrosine kinase inhibitor for relapsing forms of multiple sclerosis met pharmacokinetic and pharmacodynamic goals, data show.

For those with relapsing-remitting multiple sclerosis, treatment with vidofludimus calcium led to reductions in neurofilament light chain biomarkers as early as week 6 compared with placebo, according to a presentation at ECTRIMS 2023.

The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with relapsing forms of multiple sclerosis.

Genentech announced positive results from its global phase 2 study evaluating the investigational oral Bruton’s tyrosine kinase inhibitor fenebrutinib in adults with relapsing forms of MS.

BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.

Merck KGaA announced the FDA has paused the initiation of new patients on evobrutinib for relapsing-remitting MS, as well as those with less than 70 days exposure to the treatment in the United States.

Cycle Pharmaceuticals announced that the FDA has approved its Tascenso ODT, a bioequivalent to Gilenya, or generic fingolimod, for patients with relapsing forms of MS.

In this edition, foslevodopa-foscarbidopa improves motor symptoms in advanced PD, posterior surgery for treating cervical radiculopathy, Tysabri favored over IV in patients with relapsing-remitting MS and more.

Clinical-stage biopharmaceutical company Clene Inc. announced proof-of-concept evidence of potential neuroprotective effects of CNM-Au8, an oral therapeutic for patients with stable relapsing-remitting MS.